Research on heart failure and its treatment. Covers light exposure, heart-in-a-dish models, microRNA therapy, and surgical interventions.
Men with metabolic syndrome are nearly twice as likely to develop heart failure as those without. The condition may directly affect the heart and boost fatty deposits in arteries, say researchers. Insulin resistance is thought to play a key role in this process.
Researchers found a link between non-steroidal anti-inflammatory drugs (NSAIDs) and an increased risk of first-time hospital admissions for heart failure in the elderly. People taking indomethacin were three times more likely to be admitted due to osteoarthritis as their reason for taking NSAIDs.
A new study suggests that lixivaptan, a drug blocking vasopressin, is as effective as diuretics in reducing fluid retention in patients with congestive heart failure while also retaining proper sodium levels. The drug may offer an alternative treatment for heart failure patients and help clarify the role of vasopressin in water retention.
Researchers found that aerobic training can reverse abnormal production of certain neurohormones that cause severe symptoms of heart failure. The study suggests that exercise may be a novel non-pharmacological aid for improving functional capacity, systolic function, and quality of life in heart failure patients.
A study by University of California - San Francisco researchers found that the prostate drug doxazosin blocks alpha 1-adrenergic receptors in heart muscle cells, increasing risk of heart failure. The study suggests blocking these receptors may be a direct cause of heart failure.
Statins have been shown to significantly reduce all-cause mortality in patients treated early for acute coronary syndromes, with a moderate reduction in stroke risk. Beta-blockers also demonstrate improved survival benefits when prescribed at discharge for heart failure patients, reducing the risk of death by half.
Researchers analyzed data from 30,324 heart attack patients treated at U.S. hospitals and found that the BNP test was primarily used on high-risk patients with congestive heart failure or older age. However, younger and seemingly healthier patients with elevated BNP levels were at a two to four times greater risk of dying in the hospital.
Recent studies have improved safety and effectiveness in treating patients with acute coronary syndromes, enhancing the management of cardiovascular disease. These advancements include innovative therapies such as bivalirudin and pexelizumab, which aim to reduce major bleeding risks while maintaining efficacy.
Researchers found that early placement of cardiac resynchronization therapy devices can prolong patient lives and reduce rehospitalizations. The study analyzed data from 5,791 patients and showed a significant reduction in deaths and rehospitalizations among those who received the devices.
Researchers found that people with diabetes from different ethnic groups have varying levels of muscle mass in the left ventricle, a key indicator of heart health. In white, African-American, and Hispanic individuals, increased muscle mass was linked to subclinical atherosclerosis and high blood pressure.
A blood test measuring NT-proBNP levels can accurately predict one-year mortality risk in patients with shortness of breath, regardless of underlying heart failure diagnosis. The study suggests that this test should be routinely used to identify high-risk patients needing more intensive treatment and follow-up.
Researchers created a modified form of troponin I to improve cardiac function in mice and damaged human heart cells. The protein helps the heart respond to stress by boosting performance during periods of hardship.
A double-blind study found that acetazolamide significantly improved patient perception of sleep quality and reduced daytime fatigue in heart failure patients with sleep apnea. The medication showed promise in reducing sleep-related breathing disorders, which may also improve cardiac function.
A study found that one-third of congestive heart failure patients had low thiamin levels, highlighting the importance of diet in managing serious conditions. Vitamin supplements may help prevent thiamin deficiency and improve patient outcomes.
Researchers have developed a strategy to deliver PDGF-BB to the infarcted heart using injectable self-assembling peptide nanofibers, protecting cardiomyocytes from death and preserving cardiac function. The therapy reduced infarct size and improved cardiac function in rats.
A new blood test using NT-proBNP can accurately diagnose heart failure in patients with kidney disease, comparable to BNP testing. The study found that kidney disease does not affect the diagnostic accuracy of NT-proBNP when used properly.
The African-American Heart Failure Trial showed that patients treated with the medication had lower health care costs, averaging $15,384 over a 12-month period. The study found that the medication was cost-effective, even when factoring in the cost of the drug itself.
A CU-Boulder study found that moderate exercise extended the life expectancy of lab rats carrying a genetic blueprint for heart failure by at least 10 percent to 15 percent. This suggests low-intensity exercise may have benefits in early stages of congestive heart failure.
A study published in The Lancet found that good adherence to medication is associated with lower all-cause mortality in chronic heart failure patients. Patients who took more than 80% of their prescribed medication had a lower risk of death compared to those who took less, even when not taking any treatment.
Exercise has been shown to delay the onset of heart failure and improve survivability in rats with spontaneously hypertensive heart failure. The study also found that low-intensity exercise suppressed many physiological changes associated with CHF, including alterations in myosin heavy chain isoform expression and cardiac cell morphology.
The RAPID-CHF trial found that ultrafiltration therapy was safe and effective for patients with acute decompensated heart failure, removing more fluid and improving symptoms compared to standard treatment with intravenous diuretics. A larger trial is underway to compare its effectiveness.
A study published in JAMA Network found that US Medicare beneficiaries with heart failure had significantly better 30-day mortality rates compared to Canadian patients. However, one-year mortality rates were similar between the two groups.
A study of 2,730 men and women aged 70 to 79 found that subclinical hypothyroidism was associated with a higher rate of incident and recurrent congestive heart failure. In contrast, no association was found between subclinical hypothyroidism and coronary heart disease or stroke.
A recent study by Yale University researchers found that US Medicare patients with heart failure have a lower risk of dying within 30 days compared to their Canadian counterparts. However, the difference in long-term survival rates is negligible. The study suggests that the American system may excel at acute care, while the Canadian sy...
An international multi-center study confirmed the usefulness of a blood test in diagnosing and predicting the short-term risk of death in patients with heart failure. The study, which analyzed data from over 1,200 patients, found that the test was strongly predictive of mortality within two months of symptom onset.
A Mayo Clinic study has identified a significant increase in mortality from stroke among patients with heart failure. The research found that older individuals with previous strokes or diabetes were more likely to experience a stroke, leading to a higher risk of death.
Researchers found that people with nonsystolic heart failure can refill their hearts properly, but struggle with pumping blood during exercise. This challenges conventional wisdom and suggests alternative therapies, such as pacemakers or drugs that enhance blood vessel dilation, may be beneficial for these patients.
Researchers found that GRK2 increases in the adrenal gland, leading to high catecholamine release and desensitization of alpha-adrenergic receptors. Reducing GRK2 levels improves receptor function and reduces catecholamine release.
A study published in the Mayo Clinic found that women with congestive heart failure are less likely to receive cardiac resynchronization therapy but survive longer after implantation. The study revealed a significant gender bias, with women outperforming men in terms of long-term survival.
A two-year study involving over 2,500 heart failure patients found that hospitals that cooperated to deliver proven care and educate patients saw lower death rates and rehospitalization rates. The project used a toolkit of standard admission orders, clinical pathways, and discharge checklists to ensure optimal care.
A new study found that left ventricular assist devices (LVADs) can significantly extend the lives of patients with end-stage heart failure. The device reduced mortality risk by 50% at six and 12 months, extending average life span from 3.1 months to over 10 months.
A study found that low VO2max levels are a significant predictor of long-term mortality in patients with coronary artery disease. Patients with a VO2max below 18 ml/kg/min had a high risk of dying within 10 years, even after adjusting for age and other factors.
UT Southwestern researchers found that heart failure patients with impaired skin-blood flow responses are at risk of heat-related complications. The study suggests that these patients should be more aware of the heat and seek shade or air-conditioned environments if feeling overheated.
A randomized controlled trial found that therapy guided by pulmonary artery catheter monitoring did not improve survival or reduce hospital stays for patients with severe heart failure. However, the study suggests that PAC monitoring may be beneficial for patients who do not respond to initial therapy.
CK-1827452 selectively activates cardiac myosin, increasing contractility without changes in cellular calcium transient. The drug demonstrates improvement in cardiac function and output in a dog model of heart failure, supporting its therapeutic hypothesis.
A recent study published in the Proceedings of the National Academy of Sciences has identified a molecular defect in specialized proteins called ryanodine receptors (RyRs) as a possible cause of heart failure. The RyRs malfunction, leading to calcium imbalances that prevent the heart from contracting effectively and relaxing adequately.
A large analysis of Medicare records suggests that aspirin is not harmful and may even lower mortality rates in patients with heart failure and coronary artery disease. However, the debate remains controversial, with some experts recommending limiting or avoiding aspirin use for these patients.
A study found that heart failure patients with high predicted risk of death within a year are less likely to receive appropriate medications, including ACE inhibitors and beta-adrenoreceptor antagonists. The researchers suggest underappreciation of therapy benefits and multiple comorbid conditions may contribute to the treatment mismatch.
A study of 32 patients with heart failure found that those experiencing depression had nearly twice the levels of tumor necrosis factor alpha (TNF-alpha) in their blood. This increase was associated with worsened heart function, as TNF-alpha promotes inflammation and reduces the heart's ability to pump blood effectively.
The Cardiac Insufficiency BIsoprolol Study III suggests starting patients on bisoprolol may reduce the risk of death, especially in the first year of treatment. The study found no significant differences in efficacy or tolerability between bisoprolol and ACE inhibitor initiation strategies.
A study of Euro Heart Survey data reveals significant gender disparities in the diagnosis, treatment, and outcome of patients with heart failure and coronary artery disease. Women tend to be older, have more comorbidities, and are less likely to receive certain treatments.
Resynchronization therapy has shown efficacy in a specific subgroup of patients with heart failure, improving hemodynamic benefits, exercise tolerance, quality of life, and mortality. However, controversies surround its role in narrow QRS, atrial fibrillation, or right ventricular failure, as well as patient selection, due to high costs.
The updated guidelines focus on prolonging life, reducing morbidity, and improving quality of life for patients with chronic heart failure. New neurohormonal antagonists, ACE-inhibitors, beta-blockers, and diuretics are key components of therapy.
The ESSENTIAL trial found that low-dose oral enoximone therapy improved exercise capacity and reduced hospitalization rates in patients with advanced heart failure. However, the study also showed no significant difference in mortality rates between the enoximone and placebo groups.
The study evaluates the feasibility and effectiveness of continuous telemonitoring of multiple disease-relevant parameters in patients with chronic heart failure. The results show that treatment can be adjusted before deterioration, leading to a gain in feeling of security and reduced hospital re-admissions.
The SIRIUS II clinical trial demonstrated dose-dependent favorable hemodynamic effects and improvements in cardiac output and dyspnea score in patients with acute decompensated congestive heart failure (ADHF). Ularitide was well-tolerated, preserving kidney function during treatment.
A telemonitoring system tracks patients' vital parameters at home, enabling early detection of hemodynamic imbalance and prompt intervention. The study found improved health outcomes and reduced hospital re-admissions in patients with chronic heart failure.
Acute heart failure is a significant concern, affecting approximately 30% of acute coronary syndrome patients, with female patients showing higher prevalence rates. Hospitalizations for heart failure are comparable to myocardial infarctions, with high mortality rates during hospitalization and follow-up.
A recent international survey found that nearly 90% of Europeans are aware of heart failure, but only 3% can identify its symptoms. The study also revealed major misconceptions about the condition, including the notion that it is a normal consequence of aging or that modern drugs cannot prevent its development.
Researchers at Thomas Jefferson University have discovered a potential biomarker, GRK2, that can predict the severity of heart failure. Elevated levels of this enzyme in the blood are associated with more severe heart failure and may help identify patients who would benefit from specific treatments.
Patients with heart failure and low hemoglobin levels are at increased risk of complications, including hospitalization and mortality. Studies show that treating anemia may reduce the risk of death by up to 22% in these patients.
Researchers have discovered that during early stages of heart failure, the heart uses too much fatty acid and not enough carbohydrate; later on, it doesn't use enough fat. This new knowledge can lead to better treatments, but the existing drugs don't remedy the inefficiency.
Two studies using standardized measures found that hospitals improved on 15 of 18 clinical performance measures, but didn't show significant reductions in early deaths from heart attacks and injuries during delivery. The findings suggest that higher levels of adherence with evidence-based guidelines are achievable, but may be somewhat ...
A study of 3,558 US hospitals found that patients received inadequate care for six quality indicators, with performance varying by region, hospital type, and profit status. Hospitals in the Northeast and Midwest scored higher than those in the West and South, while not-for-profit hospitals outperformed for-profits.
A study found that insulin resistance is a predictor of congestive heart failure (CHF) in elderly men, independent of diabetes and other established risk factors. Insulin resistance was also associated with more severe disease and a worse prognosis in patients with CHF.
PediPump, a small rotary dynamic VAD, demonstrates excellent hemodynamic performance in children. Researchers plan to further reduce its size to enable implantation as a totally implantable pediatric VAD.
The study found significant variations in the quality of heart failure treatment across US hospitals, with only 24% of patients receiving complete discharge instructions. Hospitals with better performance measures had fourfold lower mortality rates and 70% more patients given discharge information.
Researchers at Duke University Medical Center have made a breakthrough in understanding the role of phosphoinositide 3-kinase (PI(3)K) in heart failure. They found that preventing PI(3)K's activation could block the loss of heart receptors, potentially improving heart function in patients with heart failure.
A large registry study found that vasodilators, such as nitroglycerin and nesiritide, have a lower in-hospital mortality rate compared to positive inotropes like dobutamine and milrinone for treating acute decompensated heart failure. The study suggests reserving inotropes for patients who fail with vasodilators or are severely ill.
The HealthGrades Women's Health Outcomes in U.S. Hospitals study found a significant gap in women's cardiac and stroke outcomes between top-performing and poor-performing hospitals. The best-performing hospitals showed a 39% lower risk-adjusted mortality rate than the poorest-performing hospitals for cardiovascular disease.